tiprankstipranks
CG Oncology, Inc. (CGON)
NASDAQ:CGON
US Market
CGON
CG Oncology, Inc.
RESEARCH TOOLSreports
Want to see CGON full AI Analyst Report?

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

365 Followers
See the Price Targets and Ratings of:

CGON Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
CG
Oncology, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$91.80
▲(32.43% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $91.80 with a high forecast of $108.00 and a low forecast of $79.00. The average price target represents a 32.43% change from the last price of $69.32.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","46":"$46","67":"$67","88":"$88","109":"$109"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$91.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$79.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,46,67,88,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.19,74.02153846153846,76.85307692307693,79.68461538461538,82.51615384615384,85.34769230769231,88.17923076923077,91.01076923076923,93.84230769230768,96.67384615384616,99.50538461538461,102.33692307692309,105.16846153846154,{"y":108,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.19,72.77538461538461,74.36076923076922,75.94615384615385,77.53153846153846,79.11692307692307,80.70230769230768,82.28769230769231,83.87307692307692,85.45846153846153,87.04384615384615,88.62923076923076,90.21461538461539,{"y":91.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.19,71.79076923076923,72.39153846153846,72.99230769230769,73.59307692307692,74.19384615384615,74.79461538461538,75.39538461538461,75.99615384615385,76.59692307692308,77.19769230769231,77.79846153846154,78.39923076923077,{"y":79,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.34,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.19,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$108.00Average Price Target$91.80Lowest Price Target$79.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CGON
David Dai
UBS
UBS
$90
Buy
29.83%
Upside
Assigned
08/21/26
UBS Keeps Their Buy Rating on CG Oncology, Inc. (CGON)
Morgan Stanley Analyst forecast on CGON
Sean Laaman
Morgan Stanley
Morgan Stanley
$93
Buy
34.16%
Upside
Assigned
08/17/26
Morgan Stanley Sticks to Their Buy Rating for CG Oncology, Inc. (CGON)
Truist Financial Analyst forecast on CGON
Gregory Renza
Truist Financial
Truist Financial
$85
Buy
22.62%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: CG Oncology, Inc. (NASDAQ: CGON) and Zimmer Biomet Holdings (NYSE: ZBH)
LifeSci Capital Analyst forecast on CGON
Sam Slutsky
LifeSci Capital
LifeSci Capital
$108
Buy
55.80%
Upside
Reiterated
08/07/26
CG Oncology: Buy Rating Reaffirmed with Unchanged $108 Price Target on Cretostimogene Clinical Catalysts and Clear Regulatory Path
H.C. Wainwright Analyst forecast on CGON
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$100
Buy
44.26%
Upside
Reiterated
08/07/26
Analysts' Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
Piper Sandler Analyst forecast on CGON
Kelsey Goodwin
Piper Sandler
Piper Sandler
$82→$85
Buy
22.62%
Upside
Reiterated
08/07/26
CG Oncology, Inc. (CGON) Gets a Buy from Piper Sandler
Bank of America Securities Analyst forecast on CGON
Alec Stranahan
Bank of America Securities
Bank of America Securities
$87→$88
Buy
26.95%
Upside
Reiterated
08/07/26
Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)
RBC Capital Analyst forecast on CGON
Leonid Timashev
RBC Capital
RBC Capital
$81→$79
Buy
13.96%
Upside
Reiterated
08/06/26
CG Oncology, Inc. (CGON) Receives a Buy from RBC Capital
JonesTrading Analyst forecast on CGON
Boris Peaker
JonesTrading
JonesTrading
$85
Buy
22.62%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Annexon Biosciences (ANNX), CG Oncology, Inc. (CGON)
Cantor Fitzgerald Analyst forecast on CGON
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$105
Buy
51.47%
Upside
Reiterated
08/06/26
Analysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), CG Oncology, Inc. (CGON)
Wolfe Research Analyst forecast on CGON
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (NASDAQ: OLMA) and CG Oncology, Inc. (NASDAQ: CGON)
Wedbush Analyst forecast on CGON
Robert Driscoll
Wedbush
Wedbush
$80
Buy
15.41%
Upside
Reiterated
05/18/26
Wedbush Remains a Buy on CG Oncology, Inc. (CGON)
TD Cowen Analyst forecast on CGON
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
J.P. Morgan Analyst forecast on CGON
Brian Cheng
J.P. Morgan
J.P. Morgan
$91→$96
Buy
38.49%
Upside
Assigned
05/11/26
CG Oncology price target raised to $96 from $91 at JPMorganCG Oncology price target raised to $96 from $91 at JPMorgan
Guggenheim Analyst forecast on CGON
Bradley Canino
Guggenheim
Guggenheim
$90
Buy
29.83%
Upside
Reiterated
02/27/26
Guggenheim Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CGON
David Dai
UBS
UBS
$90
Buy
29.83%
Upside
Assigned
08/21/26
UBS Keeps Their Buy Rating on CG Oncology, Inc. (CGON)
Morgan Stanley Analyst forecast on CGON
Sean Laaman
Morgan Stanley
Morgan Stanley
$93
Buy
34.16%
Upside
Assigned
08/17/26
Morgan Stanley Sticks to Their Buy Rating for CG Oncology, Inc. (CGON)
Truist Financial Analyst forecast on CGON
Gregory Renza
Truist Financial
Truist Financial
$85
Buy
22.62%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: CG Oncology, Inc. (NASDAQ: CGON) and Zimmer Biomet Holdings (NYSE: ZBH)
LifeSci Capital Analyst forecast on CGON
Sam Slutsky
LifeSci Capital
LifeSci Capital
$108
Buy
55.80%
Upside
Reiterated
08/07/26
CG Oncology: Buy Rating Reaffirmed with Unchanged $108 Price Target on Cretostimogene Clinical Catalysts and Clear Regulatory Path
H.C. Wainwright Analyst forecast on CGON
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$100
Buy
44.26%
Upside
Reiterated
08/07/26
Analysts' Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
Piper Sandler Analyst forecast on CGON
Kelsey Goodwin
Piper Sandler
Piper Sandler
$82→$85
Buy
22.62%
Upside
Reiterated
08/07/26
CG Oncology, Inc. (CGON) Gets a Buy from Piper Sandler
Bank of America Securities Analyst forecast on CGON
Alec Stranahan
Bank of America Securities
Bank of America Securities
$87→$88
Buy
26.95%
Upside
Reiterated
08/07/26
Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)
RBC Capital Analyst forecast on CGON
Leonid Timashev
RBC Capital
RBC Capital
$81→$79
Buy
13.96%
Upside
Reiterated
08/06/26
CG Oncology, Inc. (CGON) Receives a Buy from RBC Capital
JonesTrading Analyst forecast on CGON
Boris Peaker
JonesTrading
JonesTrading
$85
Buy
22.62%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Annexon Biosciences (ANNX), CG Oncology, Inc. (CGON)
Cantor Fitzgerald Analyst forecast on CGON
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$105
Buy
51.47%
Upside
Reiterated
08/06/26
Analysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), CG Oncology, Inc. (CGON)
Wolfe Research Analyst forecast on CGON
Kalpit Patel
Wolfe Research
Wolfe Research
―
Hold
―
Reiterated
05/26/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Olema Pharmaceuticals (NASDAQ: OLMA) and CG Oncology, Inc. (NASDAQ: CGON)
Wedbush Analyst forecast on CGON
Robert Driscoll
Wedbush
Wedbush
$80
Buy
15.41%
Upside
Reiterated
05/18/26
Wedbush Remains a Buy on CG Oncology, Inc. (CGON)
TD Cowen Analyst forecast on CGON
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
CG Oncology Earns Buy Rating as Analyst Sees High Phase III Success Odds and Strengthened BLA Timeline for Lead Asset Creto
J.P. Morgan Analyst forecast on CGON
Brian Cheng
J.P. Morgan
J.P. Morgan
$91→$96
Buy
38.49%
Upside
Assigned
05/11/26
CG Oncology price target raised to $96 from $91 at JPMorganCG Oncology price target raised to $96 from $91 at JPMorgan
Guggenheim Analyst forecast on CGON
Bradley Canino
Guggenheim
Guggenheim
$90
Buy
29.83%
Upside
Reiterated
02/27/26
Guggenheim Sticks to Its Buy Rating for CG Oncology, Inc. (CGON)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

3 Months
Alec StranahanBank of America Securities
Success Rate
10/12 ratings generated profit
83%
Average Return
+22.35%
Copying Alec Stranahan's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +22.35% per trade.
1 Year
Tyler Van BurenTD Cowen
Success Rate
11/11 ratings generated profit
100%
Average Return
+110.48%
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +110.48% per trade.
2 Years
Tyler Van BurenTD Cowen
Success Rate
11/11 ratings generated profit
100%
Average Return
+151.59%
Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +151.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
8
5
4
0
Buy
23
32
25
23
17
Hold
0
2
2
2
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
42
32
29
17
In the current month, CGON has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 91.80.
Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.83 with a range of -$0.96 to -$0.66. The previous quarter’s EPS was -$0.90. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.
Next quarter’s earnings estimate for CGON is -$0.83 with a range of -$0.96 to -$0.66. The previous quarter’s EPS was -$0.90. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $548.00K with a range of $0.00 to $1.18M. The previous quarter’s sales results were $1.16M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.
Next quarter’s sales forecast for CGON is $548.00K with a range of $0.00 to $1.18M. The previous quarter’s sales results were $1.16M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?
Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 91.80.
    What is CGON’s upside potential, based on the analysts’ average price target?
    CG Oncology, Inc. has 32.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CGON a Buy, Sell or Hold?
          CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is CG Oncology, Inc.’s price target?
            The average price target for CG Oncology, Inc. is 91.80. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $108.00 ,the lowest forecast is $79.00. The average price target represents 32.43% Increase from the current price of $69.32.
              What do analysts say about CG Oncology, Inc.?
              CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of CGON?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.